Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.54 |
| ▸ | CCND1 | P24385 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | TTK | P33981 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | CCNK | O75909 | 2/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CCND3 | P30281 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269204 | 0.80 | EGFR (0.65) | EGFRCDK2CCNKCCNA2CCND3 | |
| Hydrochloric Acid SCHEMBL264469 | 0.80 | EGFR (0.64) | EGFRCDK2CCNKCCNA2CCND3 | |
| SCHEMBL270386 | 0.78 | CDK4 (0.67) | CDK4CCND1EGFRCDK2CDK1 | |
| SCHEMBL30620425 | 0.78 | CDK4 (0.67) | CDK4CCND1EGFRCDK2CDK1 | |
| SCHEMBL1355371 | 0.78 | EGFR (0.50) | CDK4CCND1EGFRTTKCDK2 | |
| SCHEMBL23010815 | 0.77 | TTK (0.68) | EGFRTTKBRD4 | |
| SCHEMBL264391 | 0.76 | TTK (0.50) | CDK4CCND1EGFRTTKCDK2 | |
| SCHEMBL12064950 | 0.75 | CDK4 (0.62) | CDK4CCND1EGFRCDK2CDK1 | |
| SCHEMBL14634748 | 0.73 | CDK4 (0.56) | CDK4CCND1EGFRCDK2CDK1 | |
| SCHEMBL29813554 | 0.73 | EGFR (0.62) | CDK4CCND1EGFRTTKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | CDK4 117/4885CCND1 1012/4885EGFR 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.